Double-blind trial of a new topical corticosteroid in a US naval hospital
Authors: Levy, J; Highly, FM, Jr
Military Medicine 139:728–730.
HERO ID: 4934150
IPA COPYRIGHT: ASHP Fluocinonide, formulated at a concentration of 0.05% in FAPG base, (stearyl alcohol, . . .
IPA COPYRIGHT: ASHP Fluocinonide, formulated at a concentration of 0.05% in FAPG base, (stearyl alcohol, glycerine, polyethylene glycol, and propylene glycol) was evaluated in a double-blind study conducted on 56 patients with symmetrical, steroid-responsive lesions. There were 25 cases of psoriasis, 22 of atopic dermatitis, and 9 miscellaneous cases. Patients were given 2 tubes of medication at each visit, one labeled right side, the other labeled left side. The cream was applied twice daily. After the initial evaluation, patients were seen at intervals of approximately 7, 14, and 21 days. Results in all dermatoses were quite good with fluocinonide when compared with placebo. A number of patients complained of minor side effects such as burning, itching, dryness, and scaling. One patient dropped out because the lesions appeared worsened after the 1 week. Results appear to confirm the clinical efficacy of the formulation in the treatment of corticosteroid responsive dermatoses.